The role of ultrasound in first-trimester screening after the introduction of NIPT as a service of public health insurance – a consensus statement of the Fetal Medicine Foundation (FMF) Germany

Die Rolle des Ersttrimester-Screenings nach Einführung von NIPT als Kassenleistung. Ein Konsensus-Statement der Fetal Medicine Foundation (FMF) Deutschland

Authors
Eberhard Merz1©, Bernd Eiben2, Christian Thode3, Bernhard-Joachim Hackelöer4, Renaldo Faber5©, Sevgi Tercanli6, Rudolf Alkier7

Affiliations
1 Obstetrics & Gynecology, Centre for Ultrasound and Prenatal Medicine, Frankfurt, Germany
2 Institut für Klinische Genetik Nordrhein, Labor Eiben Glaubitz, Essen, Germany
3 Laboratoriumsmedizin, MVZ wagnerstibbe für Laboratoriumsmedizin und Pathologie GmbH, Göttingen, Germany
4 Gynecology and Prenatal Medicine, Pränatale-Cynäkologie-Mammasonografie Hamburg, Praxis, Hamburg, Germany
5 Leipzig, Center of Prenatal Medicine, Leipzig, Germany
6 Praxis, Universitätsspital Basel, Basel, Switzerland
7 Clinical Chemistry, Labor Enders Prof Dr med Gisela Enders and Colleagues MVZ GbR, Stuttgart, Germany

Key words
Combined first-trimester screening, contingent screening, cell-free fetal DNA, prenatal ultrasound, chromosome anomalies

ABSTRACT
Combined first-trimester screening (FTS) and noninvasive prenatal testing (NIPT) have been proven to be reliable noninvasive procedures to detect the most common chromosomal abnormalities (trisomies 21, 18, 13) in the first trimester. The aim of this paper is to demonstrate the strengths and limitations of these two procedures and to give a consensus statement of the Fetal Medicine Foundation (FMF) Germany on how to use the two techniques in the first trimester after the introduction of NIPT as a service of the statutory health insurance companies in Germany.

ZUSAMMENFASSUNG
Das kombinierte Ersttrimester-Screening und der nichtinvasive DNA-Test (NIPT) haben sich als verlässliche nichtinvasive Verfahren zur Diagnostik der häufigsten Chromosomenanomalien (Trisomien 21, 18, 13) im 1. Trimenon gezeigt. Das Ziel dieser Publikation ist es, die Stärken, wie auch die Limitierungen, beider Verfahren aufzuzeigen und ein Konsensus-Statement der Fetal Medicine Foundation (FMF) Deutschland abzugeben, wie beide Techniken im 1. Trimenon eingesetzt werden sollen, nachdem NIPT als Kassenleistung in Deutschland eingeführt wurde.

Introduction
For two decades, combined first-trimester screening (FTS), including data on maternal age, ultrasound markers, and biochemical parameters, had been the most reliable noninvasive procedure to calculate the risk of chromosomal abnormalities between 11 + 0 and 13 + 6 weeks of gestation [1, 2, 3, 4, 5]. The introduction of noninvasive prenatal tests by sequencing cell-free placen-
The role of... Ultraschall in Med 2023; 44: 600–605 | © 2023. Thieme. All rights reserved.
The role of NIPT allows two different application models: 1. NIPT as a first-line (German Gene Diagnostics Act [37]). Qualified pre- and post-test counseling is necessary. However, it is only a test for trisomies 21, 18, and 13 and sex chromosome aberrations [31, 32], but has currently no value in the detection of many other chromosomal abnormalities.

NIPT is an advanced screening test for trisomies 21, 18, and 13 and sex chromosome aberrations [31, 32], but has currently no value in the detection of many other chromosomal abnormalities. NIPT has limited value in the detection of deletions [28, 29]. NIPT may produce false-positive results: trisomy 21 (0.04%), trisomy 18 (0.04%), trisomy 13 (0.04%) and sex chromosome aneuploidies (SCA) (monosomy X 0.14%, SCA other than monosomy X (0.004%) [26], and false-negative results [33].

NIPT does not allow the detection of structural defects of the fetus. NIPT is limited to singleton and twin pregnancies. NIPT is contraindicated in higher degree multiples. NIPT is contraindicated in vanishing twin.

The time until the result is available is longer than with first-trimester screening. Low fetal cfDNA fraction <4% in maternal blood is seen in about 2–5% of the cases [34] and results with low fetal fractions are of limited value or fail to provide a result after one blood drawing.

In obese pregnant women the risk of a low fetal cfDNA fraction in maternal blood is increased [35]. In pregnancies with failed cfDNA test, fetal chromosomal abnormalities are over-represented [34, 36].

However, it is only a test for trisomies 21, 18, and 13 and sex chromosomal abnormalities, if performed without any ultrasound examination, no structural abnormalities or other genetic anomalies can be detected. Contingent screening using FTS with a qualified fetal anatomy scan first allows exclusion or detection of structural defects and – after risk assessment – differentiation between high-risk, intermediate-risk and low-risk groups [5, 41]. If there is normal sonoanatomy and the risk assessment shows a result in the intermediate or low-risk group, NIPT can be performed as soon as the FTS risk assessment is available or, alternatively, NIPT can be performed directly after the FTS anatomy scan has shown no structural abnormality. For cases with detected fetal abnormalities (suspicous ultrasound marker or structural abnormality), NIPT is not recommended, and invasive testing should be performed instead. However, the enactment of a contingent model requires an already well-established national screening program based on combined first-trimester screening including NT measurement and serum biochemistry [38]. In all countries where a qualified and standardized ultrasound examination and a qualified FTS AUDIT are guaranteed (such as with FMF UK or FMF Germany) [5, 41], a contingent screening [40, 42, 43] seems to be the preferred approach.

With the introduction of NIPT as a service covered by the statutory health insurance companies in Germany – while FTS is still a service for self-payers – a tremendous increase in NIPT and a decrease in FTS could be observed [44] (Fig. 2).

NIPT, performed as first-line screening without any prior ultrasound examination, does not allow the detection of any fetal structural malformations, early fetal growth restriction, twin abnormalities, or abnormal placental structure. In contrast, qualified combined first-trimester screening with a detailed ultrasound ex-

### Table 3 Structural fetal defects detectable and not detectable with 3D ultrasound in the first trimester [25].

<table>
<thead>
<tr>
<th>Structural defects detectable with 3D ultrasound in the first trimester</th>
<th>Structural defects not detectable with 3D ultrasound in the first trimester</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yolk sac abnormalities</td>
<td>Microcephaly</td>
</tr>
<tr>
<td>Umbilical cysts</td>
<td>Macrocephaly</td>
</tr>
<tr>
<td>Exencephaly/anencephaly</td>
<td>Ventriculomegaly</td>
</tr>
<tr>
<td>Encephalocele</td>
<td>Agensis of corpus callosum</td>
</tr>
<tr>
<td>Holoprosencephaly</td>
<td>Subtle cardiac defects</td>
</tr>
<tr>
<td>Facial clefts/absent nasal bone/retrognathia</td>
<td>Lung abnormalities</td>
</tr>
<tr>
<td>Low set ears</td>
<td>Bowel obstruction</td>
</tr>
<tr>
<td>Spina bifida</td>
<td>Hydroenphrosis</td>
</tr>
<tr>
<td>Severe cardiac defects</td>
<td>Bladder extrophy</td>
</tr>
<tr>
<td>Abdominal wall defects</td>
<td>Achondroplasia</td>
</tr>
<tr>
<td>Hydrops</td>
<td>Pena-Shokeir syndrome</td>
</tr>
<tr>
<td>Megacystsis</td>
<td></td>
</tr>
<tr>
<td>Achondrogenesis</td>
<td></td>
</tr>
<tr>
<td>Limb defects, polydactyly</td>
<td></td>
</tr>
<tr>
<td>Body stalk anomaly</td>
<td></td>
</tr>
<tr>
<td>Kartagener syndrome</td>
<td></td>
</tr>
<tr>
<td>Severe amniotic band syndrome</td>
<td></td>
</tr>
<tr>
<td>Conjoined twins</td>
<td></td>
</tr>
<tr>
<td>Single umbilical artery</td>
<td></td>
</tr>
</tbody>
</table>

### Table 4 Advantages of NIPT (cell-free DNA analysis).

- NIPT can be performed reliably from 10 weeks of gestation and does not have an upper gestational limit such as FTS.
- Simplicity of the procedure, no special training required. However, qualified pre- and post-test counseling is necessary.
- High detection rate of trisomy 21 (99.7%), trisomy 18 (97.9%), and trisomy 13 (99.0%) and sex chromosome aneuploidies (SCA) (monosomy X 95.8%, SCA other than monosomy X (100%) [26] and a few individual deletions such as 22q11.2 [27, 28, 29] or 13q31.1 [30].
- The number of invasive procedures can be reduced.

### Table 5 Limitations of NIPT.

- NIPT is an advanced screening test for trisomies 21, 18, and 13 and sex chromosome aberrations [31, 32], but has currently no value in the detection of many other chromosomal abnormalities.
- NIPT has limited value in the detection of deletions [28, 29].
- NIPT may produce false-positive results: trisomy 21 (0.04%), trisomy 18 (0.04%), trisomy 13 (0.04%) and sex chromosome aneuploidies (SCA) (monosomy X 0.14%, SCA other than monosomy X (0.004%) [26], and false-negative results [33].
- NIPT does not allow the detection of structural defects of the fetus.
- NIPT is limited to singleton and twin pregnancies.
- NIPT is contraindicated in higher degree multiples.
- NIPT is contraindicated in vanishing twin.
- The time until the result is available is longer than with first-trimester screening.
- Low fetal cfDNA fraction <4% in maternal blood is seen in about 2–5% of the cases [34] and results with low fetal fractions are of limited value or fail to provide a result after one blood drawing.
- In obese pregnant women the risk of a low fetal cfDNA fraction in maternal blood is increased [35]. In pregnancies with failed cfDNA test, fetal chromosomal abnormalities are over-represented [34, 36].

- NIPT is not recommended, and invasive testing should be performed instead. However, the enactment of a contingent model requires an already well-established national screening program based on combined first-trimester screening including NT measurement and serum biochemistry [38]. In all countries where a qualified and standardized ultrasound examination and a qualified FTS AUDIT are guaranteed (such as with FMF UK or FMF Germany) [5, 41], a contingent screening [40, 42, 43] seems to be the preferred approach.
- With the introduction of NIPT as a service covered by the statutory health insurance companies in Germany – while FTS is still a service for self-payers – a tremendous increase in NIPT and a decrease in FTS could be observed [44] (Fig. 2).
- NIPT, performed as first-line screening without any prior ultrasound examination, does not allow the detection of any fetal structural malformations, early fetal growth restriction, twin abnormalities, or abnormal placental structure. In contrast, qualified combined first-trimester screening with a detailed ultrasound ex-

### Table 5 Limitations of NIPT.

- NIPT is an advanced screening test for trisomies 21, 18, and 13 and sex chromosome aberrations [31, 32], but has currently no value in the detection of many other chromosomal abnormalities.
- NIPT has limited value in the detection of deletions [28, 29].
- NIPT may produce false-positive results: trisomy 21 (0.04%), trisomy 18 (0.04%), trisomy 13 (0.04%) and sex chromosome aneuploidies (SCA) (monosomy X 0.14%, SCA other than monosomy X (0.004%) [26], and false-negative results [33].
- NIPT does not allow the detection of structural defects of the fetus.
- NIPT is limited to singleton and twin pregnancies.
- NIPT is contraindicated in higher degree multiples.
- NIPT is contraindicated in vanishing twin.
- The time until the result is available is longer than with first-trimester screening.
- Low fetal cfDNA fraction <4% in maternal blood is seen in about 2–5% of the cases [34] and results with low fetal fractions are of limited value or fail to provide a result after one blood drawing.
- In obese pregnant women the risk of a low fetal cfDNA fraction in maternal blood is increased [35]. In pregnancies with failed cfDNA test, fetal chromosomal abnormalities are over-represented [34, 36].
amination allows the detection of the most common trisomies, triploidy, and the demonstration or exclusion of various structural defects (▶Table 3). As early prenatal screening provides more than just risk assessment of trisomies 21, 18 and 13, every pregnant woman should receive comprehensive information about current noninvasive and invasive procedures and early pre-eclampsia screening [22, 23, 46, 47].

There is broad consensus in several ultrasound societies and publications that a detailed first-trimester ultrasound examination should always be performed prior to an NIPT procedure [40, 47, 48, 49, 50, 51, 52].

Since NIPT has been covered by statutory health insurance since July 1, 2022, NIPT will become more popular and FTS biochemical screening, which is subject to a fee, will continue to decline. The hormone parameters free β-HCG and PAPP-A will no longer have the importance they had in pre-NIPT times, but they may continue to be offered as an option, or in situations where NIPT is not recommended (e.g., vanishing twin) or in cases with very low fetal DNA fractions. On the other hand, PAPP-A is a biomarker that is also used in pre-eclampsia screening in the first trimester [23].

As a result, FMF Germany recommends performing NIPT as a contingent procedure, either once the FTS results are available (▶Fig. 3) or directly after the FTS ultrasound examination has shown no structural fetal malformation and normal NT (▶Fig. 4).

Conclusion

While NIPT is currently focusing on screening for trisomy 21, 18, 13 and sex chromosomal abnormalities only, combined first-trimester screening with a detailed ultrasound check of the fetal anatomy is of major importance for the early detection of structural defects. Consequently, NIPT should not replace combined first-trimester screening with a detailed check of the fetal morphology. Therefore, the optimal first-trimester screening approach would be to first perform a detailed ultrasound examination and a risk calculation with the basic parameters of maternal age, crown-rump length, and nuchal translucency thickness, and – for experienced operators – with the additional ultrasound parameters absence/presence of nasal bone, ductus venosus flow, and tricuspid regurgitation. If no structural abnormality is found and the risk assessment shows a result in the low-risk or intermediate-risk group, NIPT can be performed for advanced screening for trisomies 21, 18, 13 and sex chromosome aneuploidies. If a structural abnormality is detected during the ultrasound examination, NIPT is no longer advisable and instead, CVS or an amniocentesis should be performed for karyotyping (▶Fig. 3).
1. NIPT should never be performed in the first trimester without a prior ultrasound examination.

2. NIPT is currently limited to the detection of trisomy 21, 18, 13, aberrations of sex chromosomes, and individual deletions.

3. First-trimester screening between gestational weeks 11 + 0 and 13 + 6 continues to be valid since ultrasound examination makes it possible to detect not only chromosomal but also structural abnormalities.

4. In the case of sonographic detection of a fetal abnormality, direct diagnosis via invasive testing without NIPT should be performed.

5. In Germany, both NIPT and first-trimester screening are subject to the Genetic Diagnosis Act, i.e., patients must be counseled prior to the examination as well as once the results are available.

6. A normal ultrasound examination in the first trimester does not necessarily rule out fetal abnormalities. Therefore, second-trimester screening between gestational weeks 18 + 0 and 21 + 6 continues to be a standard part of prenatal testing.

as well as microarray [53] and genome sequencing [54, 55] if required.

Finally, the key statements for early prenatal screening are listed in Table 6.

Conflict of Interest

The authors declare that they have no conflict of interest.

References


